Stocks and Investing
Stocks and Investing
Tue, April 21, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Madhu Kumar Initiated (APRE) at Buy and Held Target at $900 on, Apr 21st, 2020
Madhu Kumar of Baird, Initiated "Aprea Therapeutics, Inc." (APRE) at Buy and Held Target at $900 on, Apr 21st, 2020.
Madhu has made no other calls on APRE in the last 4 months.
There is 1 other peer that has a rating on APRE. Out of the 1 peers that are also analyzing APRE, all agrees with Madhu's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $780 on, Wednesday, April 15th, 2020